In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study’s findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.
Facing Formidable Diabetic Cases with Patient Persistence & Adherence
Managing Diabetes & COVID-19 in the Wintertime
Caring for Diabetic Patients During the COVID-19 Pandemic
Anti-inflammatory, Anti-atherogenic and Cardioprotective Effects of Insulin
Physiologic Fundamentals of Impaired Glucose Metabolism
Postprandial Blood Glucose: Diabetes Control & Complications
Growing Concerns of Diabetes and Various Cancers
Diabetes Health Care Disparities in the African American Community
Updates in the Classification & Diagnosis of Type 2 Diabetes
Attaining the Best Glucose Control Safely
The Regulatory Environment for the Artificial Pancreas
Recommendations in the Diagnosis and Treatment of Gestational Diabetes
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
How Similar Are Biosimilar Insulins?
Sexual Complications and Diabetes
What Do Young Doctors Know About Diabetes Management?
Insulin Pump Practices
Inpatient and Outpatient Recommendations for Diabetes
Psychological Insulin Resistance
Antipsychotics and Metabolic Syndrome
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
NASACast Video
Mysteries Abound